Crohn Disease Clinical Trials in Houston, Texas

6 studies are recruiting for crohn disease in Houston, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO

   This phase Ib trial studies the side effects of nivolumab and to see how well it works alone and in combination with other treatments, such as ipilimumab, cabozantinib, platinum containing therapy, and fluoropyrimidine, in treating patients with autoimmune disorders and cancer that has spread from …

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT MD Anderson Cancer Center, Houston, Texas

   Locations

   52 in total

   Run by

   National Cancer Institute (NCI)

   See if you can join NCT03816345 on ClinicalTrials.gov

2. A Study to Assess the Long-Term Safety of Ustekinumab Versus Other Biologics in Patients With Crohn's Disease and Ulcerative Colitis

   The purpose of this study is to estimate and compare the incidence of overall malignancy, serious infection, and opportunistic infections between new users of ustekinumab and new users of other biologic therapies among adult participants with Crohn's disease (CD) or ulcerative colitis (UC).

   Stage

   Not phased

   Ages

   18 and older

   Site

   BAMC, Houston, Texas

   Run by

   Janssen Scientific Affairs, LLC

   See if you can join NCT04372108 on ClinicalTrials.gov

3. A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

   The purpose of this study is to evaluate how-well icotrokinra works (clinical efficacy) and how safe it is (safety) in participants with moderately to severely active Crohn's disease (CD; a long-term condition causing severe inflammation of the intestinal tract).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Victorium Clinical Research, Houston, Texas

   Locations

   370 in total

   Run by

   Janssen Research & Development, LLC

   See if you can join NCT07196722 on ClinicalTrials.gov

4. Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission

   The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ul…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Baylor College of Medicine, Houston, Texas

   Locations

   24 in total

   Run by

   Mayo Clinic

   See if you can join NCT05230173 on ClinicalTrials.gov

5. Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

   This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of …

   Stage

   Not phased

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT04751396 on ClinicalTrials.gov

6. VECTORS - A Study to Evaluate Transmural Healing as a Treatment Target in Crohn's Disease

   Transmural healing (TMH) is recognized as a potentially important measure of Crohn's disease (CD) activity but not a formal target. Observational studies suggest that TMH may be associated with better long-term outcomes. The study will evaluate TMH using noninvasive intestinal ultrasound (IUS), a p…

   Stage

   Phase 4

   Ages

   18 to 80

   Site

   Houston Methodist Hospital, Houston, Texas

   Locations

   69 in total

   Run by

   Alimentiv Inc.

   See if you can join NCT06257706 on ClinicalTrials.gov